Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Santiago Madera"'
Autor:
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo
Publikováno v:
Cell Death and Disease, Vol 14, Iss 12, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/f97153e8a240450a80194174d2482fd7
Autor:
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo
Publikováno v:
Cell Death and Disease, Vol 13, Iss 5, Pp 1-14 (2022)
Abstract Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2. Due to TNBC heterogeneity
Externí odkaz:
https://doaj.org/article/c5cf687b8b084672a59b0ffb44e8ef9e
Autor:
Andrés Imbaquingo Cabrera, J. Santiago Madera-Obando, Iván Eduardo Maldonado Noboa, José Castillo Avellán, Bárbara León-Micheli, Raúl Galárraga-Campoverde, Lennyn Estuardo Albán-León
Publikováno v:
Oncología (Ecuador). 32:224-243
Introducción: Las metástasis cerebrales (MC) representan una problemática importante de la salud pública, en promedio el 30% de los pacientes oncológicos desarrollarán MC siendo importante causa de morbilidad, ansiedad y mortalidad. El tratamie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7740161761a9e4354e0b73e11ce0498e
https://doi.org/10.33821/635
https://doi.org/10.33821/635
Autor:
Santiago Madera, Valentina C. Bulian, Sharon S. Merin, María F. Mercogliano, Roxana Schillaci, Rosalia I. Cordo Russo
Publikováno v:
Cancer Research. 83:3633-3633
The tumor microenvironment component hyaluronan (HA) induces tumor progression through the interaction with its cell surface receptor CD44. Accumulation of HA is associated with poor prognosis and resistance to the anti-ErbB-2 agent trastuzumab (TZ)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b8234863bdcbcb0d792c1d06c7ba6a7
https://doi.org/10.1158/1538-7445.am2023-3633
https://doi.org/10.1158/1538-7445.am2023-3633
Autor:
Patricia Virginia Elizalde, Franco Izzo, Maria Florencia Chervo, Sharon Salma Merin, Agustina Dupont, Violeta Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Diego Montero, Maria Florencia Mercogliano, Cecilia Jazmin Proietti, Roxana Schillaci, Santiago Madera, Rosalia Ines Cordo Russo
Publikováno v:
Journal of the Endocrine Society. 6:A872-A872
Triple negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of the receptor tyrosine kinase ErbB-2/HER2. Due to its heterogeneity, clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5548d4a29e58ce30b2c27827fc4e7e2
https://doi.org/10.1210/jendso/bvac150.1804
https://doi.org/10.1210/jendso/bvac150.1804
Autor:
Patricia Elizalde, Agustina Roldan Deamicis, Robert Oakley, Santiago Madera, Rosalía Cordo Russo, Roxana Schillaci, Cristóbal Fresno, John Cidlowski, Cecilia Proietti
Publikováno v:
Journal of the Endocrine Society. 6:A720-A720
Triple negative breast cancer (TNBC) has poor prognosis and neither established biomarkers nor therapeutic targets. On the one hand, the androgen receptor (AR), a steroid hormone receptor (SR) which is expressed in 10-53% of TNBC and proved to be cri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebb059a1b8e556528191d36a98083303
https://doi.org/10.1210/jendso/bvac150.1483
https://doi.org/10.1210/jendso/bvac150.1483
Autor:
Patricia Elizalde, Martina Belmonte, Mauro Cenciarini, Agustina Roldan Deamicis, Santiago Madera, Florencia Mercogliano, Florencia Mauro, Sofia Bruni, Rosalía Cordo Russo, Roxana Schillaci, Cecilia Proietti
Publikováno v:
Journal of the Endocrine Society. 6:A719-A719
Enhancer of Zeste homolog 2 (EZH2) is a histone methyltransferase which catalyzes the trimethylation of lysine 27 of histone H3 (H3K27me3), an epigenetic mark associated with chromatin compaction and transcriptional repression of target genes. This c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2bc5d35f8cc95dc0f93f1429a510bf9
https://doi.org/10.1210/jendso/bvac150.1481
https://doi.org/10.1210/jendso/bvac150.1481
Autor:
Patricia V Elizalde, Rosalia Cordo Russo, Santiago Madera, Sharon S Merin, María F Chervo, Esmaeil Ebrahimie, Luke Selth, Violeta A Chiauzzi, Agustina Dupont, Sabrina Barchuk, Silvina Figurelli, Daniel Lopez Della Vecchia, Pablo Guzmán, Juan C Roa, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Cecilia J Proietti, Roxana Schillaci, Theresa E Hickey, Wayne D Tilley
Publikováno v:
Journal of the Endocrine Society. 6:A878-A878
ErbB-2, a member of ErbB family of receptor tyrosine kinases, is a key oncogenic driver in breast cancer. Despite clinical efficiency of ErbB-2-targeted therapies (trastuzumab, TZ), resistance to drugs is a major issue in the clinic. While ErbB-2 is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d4fed870b0bb20a1ac5ef36bb608e15
https://doi.org/10.1210/jendso/bvac150.1817
https://doi.org/10.1210/jendso/bvac150.1817
Autor:
Santiago Madera, Franco Izzo, Maria F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Diego Montero, Sharon Merin, Maria F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Rosalia I. Cordo Russo, Patricia V. Elizalde
Publikováno v:
Cancer Research. 82:344-344
Triple negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of the receptor tyrosine kinase ErbB-2/HER2. Due to its heterogeneity, clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a57013c30e7938f3a38b13eb742d785e
https://doi.org/10.1158/1538-7445.am2022-344
https://doi.org/10.1158/1538-7445.am2022-344
Autor:
Pablo Guzmán, Juan Carlos Roa, Silvina Figurelli, Agustina Roldán Deamicis, Rosalia Ines Cordo Russo, Leandro Venturutti, Mauro E. Cenciarini, Felipe G. Gercovich, Agustina Dupont, María F. Chervo, Violeta A. Chiauzzi, Santiago Madera, Sabrina Barchuk, Daniel Lopez Della Vecchia, Cecilia Jazmín Proietti Anastasi, Patricia V. Elizalde, Matías G. Pereyra, Roxana Schillaci, Sandra L. Ares, Ernesto Gil Deza
Publikováno v:
Journal of the Endocrine Society
Hormone receptor-positive (HR+, estrogen and/or progesterone receptor-positive) and HER2-negative breast cancer (BC) subtype is a biologically heterogeneous entity that comprises 70% of BCs. This subtype includes both luminal (Lum) A- and B-like subt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd8efa62e66cc6c4af7c9a0885b65b4
http://europepmc.org/articles/PMC7208765
http://europepmc.org/articles/PMC7208765